Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 11/20 | 0.75 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.75 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.75 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3750843 | 0.90 | MAPK10 (0.66) | MAPK10MAPK9MAPK8LTA4HALDH1A1 | |
| Bentamapimod SCHEMBL2878382 | 0.86 | MAPK10 (1.00) | MAPK10MAPK9MAPK8LTA4HUSP2 | |
| Bentamapimod SCHEMBL30197744 | 0.86 | MAPK10 (1.00) | MAPK10MAPK9MAPK8LTA4HUSP2 | |
| Bentamapimod SCHEMBL29350260 | 0.86 | MAPK10 (1.00) | MAPK10MAPK9MAPK8LTA4HUSP2 | |
| Bentamapimod SCHEMBL29423429 | 0.86 | MAPK10 (1.00) | MAPK10MAPK9MAPK8LTA4HUSP2 | |
| SCHEMBL2881959 | 0.84 | MAPK10 (0.64) | MAPK10MAPK9MAPK8LTA4HUSP2 | |
| SCHEMBL3747858 | 0.84 | MAPK10 (0.86) | MAPK10MAPK9MAPK8LTA4HALDH1A1 | |
| SCHEMBL4024376 | 0.83 | MAPK10 (0.67) | MAPK10MAPK9MAPK8MKNK1USP2 | |
| SCHEMBL2878620 | 0.83 | MAPK10 (0.69) | MAPK10MAPK9MAPK8MKNK1USP2 | |
| Bentamapimod SCHEMBL4948513 | 0.81 | MAPK10 (0.89) | MAPK10MAPK9MAPK8LTA4HUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838522-B2 | Benzothiazole formulations and use thereof | ARES TRADING S.A. (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838522-B2 | Benzothiazole formulations and use thereof | ARES TRADING S.A. (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838522-B2 | Benzothiazole formulations and use thereof | ARES TRADING S.A. (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-1812072-B1 | BENZOTHIAZOLE FORMULATIONS AND USE THEREOF | ARES TRADING SA (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| EP-1812072-A2 | BENZOTHIAZOLE FORMULATIONS AND USE THEREOF | Ares Trading S.A. (CH) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006053882-A2 | BENZOTHIAZOLE FORMULATIONS AND USE THEREOF | ARES TRADING S.A. (CH) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | MGLL, MBOAT4, MBOAT1 | MAPK10 3176/4885MAPK9 3960/4885MAPK8 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.